Recent
price
P/E
ratio
div
yld
- -
ROIC.AI
•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.Scholar Rock Holding Corporation (SRRK) Presents at UBS Global Biopharma Conference 2026 Transcript
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
What Scholar Rock (SRRK) Said on Its Q3 Earnings Call
Scholar Rock Holding Corporation (SRRK) Q3 2026 Earnings Call Transcript
Scholar Rock Holding Corporation (SRRK) Reports Q3 Loss, Beats Revenue Estimates
Scholar Rock Reports Third Quarter 2026 Financial Results and Recent Business Highlights
Scholar Rock to Report Third Quarter 2026 Financial Results on November 10, 2026
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Scholar Rock Resubmits Apitegromab Marketing Authorisation Application (MAA) to European Medicines Agency (EMA) for Treatment of Children and Adults with Spinal Muscular Atrophy (SMA)
Scholar Rock (NASDAQ:SRRK) Stock Falls 5.1% – Here’s What Happened
Kuehn Law Encourages Investors of Scholar Rock Holding Corp to Contact Law Firm
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Scholar Rock Holding Corporation $SRRK Shares Bought by Engineers Gate Manager LP
Scholar Rock: Reiterating 'Strong Buy' On FDA Approval SMA And Expansions Now In Play
Here Are Tuesday’s Top Wall Street Analyst Research Calls: Autodesk, Eli Lilly, Etsy, Lear, Netskope, Nokia, Northrop Grumman, Rapid7, Rivian Automotive, Ulta Beauty, and More
Scholar Rock Holding Corporation (SRRK) Discusses FDA Approval and Clinical Impact of ISEMBYLD in SMA Treatment Transcript
Scholar Rock Marks 'Defining Moment' with First Muscle-Targeted Treatment for Spinal Muscular Atrophy
Scholar Rock prices first drug to target SMA muscle loss at $11,659 per vial
Why Scholar Rock Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket
Scholar Rock Announces FDA Approval of ISEMBYLD™ (apitegromab-mstn), the First and Only Muscle-Targeted Treatment for Children and Adults with Spinal Muscular Atrophy (SMA)